Muhammad Ubaidulhaq, MD
Interventional Pain Medicine · Marshfield, WINPI 1265735807
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $6,461 of the $8,801 with a category attached, or 73.4%. 10 manufacturers reported payments, led by Medtronic at 54.2% of the total. Reporting peaked in 2022 at $3,355 and has fallen 75.2% since, to $833 in 2025.
Across 79 payments — averaging $111.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Relievant Medsystems, Inc.$2K
- Abbott$768
- Stryker$729
- Vertos Medical, Inc.$214
- Boston Scientific$160
- plus $204 from 4 others
What the payments were for
- Travel & lodging$6,46173%
- Food & beverage$2,34027%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 41 | $4,774 |
| Relievant Medsystems, Inc. | 12 | $1,952 |
| Abbott | 4 | $768 |
| Stryker | 10 | $729 |
| Vertos Medical, Inc. | 4 | $214 |
| Boston Scientific | 3 | $160 |
| SPR Therapeutics, Inc | 2 | $135 |
| Acacia Pharma Inc | 1 | $25 |
| Saluda Medical Americas, Inc. | 1 | $24 |
| Nevro Corp. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$3,524
- INTELLIS$1,843
- INTELLIS ADAPTIVESTIM$1,093
- PROCLAIM$759
- KYPHON EXPRESS II KYPHOPAK TRAY$700
- OPTABLATE$504
- SPINEJACK$504
How this compares
$8,801 in reported general payments places this provider in the 70th percentile of 41 interventional pain medicine providers in Wisconsin.
See all interventional pain medicine providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $564 |
| Pregabalin | 18 | $194 |
| Tramadol Hcl | 53 | $124 |
| Methocarbamol | 19 | $118 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $109 |
| Gabapentin | 20 | $97 |
| Cephalexin | 37 | $90 |
| Meloxicam | 22 | $84 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Marshfield
- Christopher HowsonGreen Bay$114K
- Matthew PileckiMount Pleasant$29K
- Christina MooreMilwaukee$26K
- Nileshkumar PatelGreenfield$25K
- Daniel BrunnerNeenah$24K
- Vishal Patelde Pere$23K
- Colin StairSummit$17K
- Timothy StaackeKenosha$13K
- Richard LennertzMilwaukee$11K
- Ryan ClarkGreen Bay$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.